MedPath

ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry

Completed
Conditions
Opioid Dependence
Registration Number
NCT01422837
Lead Sponsor
Alkermes, Inc.
Brief Summary

The objective of the VIVITROL Registry is to gather real world data on opioid dependence and to provide understanding of the health economics of opioid dependence.

Detailed Description

The VIVITROL Registry is an observational, open-label, single-arm, multi-center registry of patients who have initiated treatment with VIVITROL for prevention of relapse to opioid dependence, following opioid detoxification.

The objectives of the VIVITROL Registry are:

* To describe characteristics of patients receiving VIVITROL for opioid dependence in real-world clinical practice.

* To assess clinical, health economic, and health-related quality of life (HRQOL) outcomes in a broad population of patients receiving VIVITROL in real-world clinical practice.

* To provide additional data to inform future research on VIVITROL.

Patients 18 years of age or older who have been determined by their participating prescriber to be an appropriate candidate for VIVITROL treatment may be offered enrollment into the registry. The decision to treat a patient with VIVITROL will be made by the patient's participating prescriber independent of the registry. VIVITROL will not be provided to patients enrolled in the registry in exchange for their participation; patients will receive commercially available VIVITROL via a standard prescription that will be filled through standard commercial channels.

Patients will be observed while receiving VIVITROL and for six months after they discontinue VIVITROL use. The registry is non-interventional; it will neither direct the treatment plan for enrolled patients nor define the frequency of follow-up visits of each patient. A patient's participation in the registry will not influence or direct patient treatment procedures or follow-up care. It is expected that patients will be seen at least once per month during active VIVITROL treatment to receive their monthly injection.

During the standard monthly injection visits, patients will be asked to provide detailed health economics information using a variety of questionnaires, including the EQ-5D and SF-12v2.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
403
Inclusion Criteria
  • Patient is aged 18 years or older
  • Patient is diagnosed with a current opioid dependence for which treatment with VIVITROL is being initiated
  • Patient has provided written informed consent
  • Patient is willing and able to provide the information to be collected via the registry's interviews and questionnaires
  • Patient expects to be available for ongoing registry participation
Exclusion Criteria
  • Prior use of VIVITROL

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (30)

Innovation Laboratory/PEARL

🇺🇸

Johnson City, Tennessee, United States

Arkansas Psychiatric Clinc

🇺🇸

Little Rock, Arkansas, United States

Psychotherapy Services, Etc.

🇺🇸

Groton, Connecticut, United States

Gosnold-Thorne Counseling Center

🇺🇸

Centerville, Massachusetts, United States

Jacqueline Boutrouille, MD

🇺🇸

Tamarac, Florida, United States

Jasper Health

🇺🇸

Media, Pennsylvania, United States

Adolescent and Family Health Center, PC

🇺🇸

Midlothian, Virginia, United States

PACT Atlanta

🇺🇸

Decatur, Georgia, United States

Alliance Clinical Research

🇺🇸

Winter Park, Florida, United States

Holiner Psychiatric Group

🇺🇸

Dallas, Texas, United States

Lenae White, MD, PA

🇺🇸

Dallas, Texas, United States

Assisted Recovery Centers of America

🇺🇸

Saint Louis, Missouri, United States

Urschel Recovery Science Institute

🇺🇸

Dallas, Texas, United States

Dent Neurologic Institute

🇺🇸

Amherst, New York, United States

Chessen and Associates

🇺🇸

Newport News, Virginia, United States

The NeuroBehavioral Institute of Colorado, PC

🇺🇸

Lone Tree, Colorado, United States

Atlanta Institute of Medicine and Research

🇺🇸

Atlanta, Georgia, United States

Dr. Michael Sanders

🇺🇸

Great Neck, New York, United States

Kenneth C. Russ, MD

🇺🇸

Palm Springs, California, United States

Dr. Li's Clinic

🇺🇸

Milford, Massachusetts, United States

Fakhouri Medical

🇺🇸

Hopewell Junction, New York, United States

Parallax Center

🇺🇸

New York, New York, United States

Healing Comfort Clinic

🇺🇸

Corvallis, Oregon, United States

Utah Addiction Medicine & Counseling

🇺🇸

Bountiful, Utah, United States

Amy Solomon, MD

🇺🇸

Ben Lomond, California, United States

Tarzana Treatment Centers

🇺🇸

Tarzana, California, United States

Touchstone Medical Group

🇺🇸

Clovis, California, United States

Institute of Addiction Medicine

🇺🇸

Plymouth Meeting, Pennsylvania, United States

Creekside Center for Integrative Medicine

🇺🇸

Bellevue, Washington, United States

Child and Adolescent Psychiatry

🇺🇸

Bothell, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath